<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Metab Disord</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Metab Disord</journal-id><journal-title-group><journal-title>Journal of Diabetes and Metabolic Disorders</journal-title></journal-title-group><issn pub-type="epub">2251-6581</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25654061</article-id><article-id pub-id-type="pmc">4316808</article-id><article-id pub-id-type="publisher-id">127</article-id><article-id pub-id-type="doi">10.1186/s40200-014-0127-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phylloquinone supplementation improves glycemic status independent of the effects of adiponectin levels in premonopause women with prediabetes: a double-blind randomized controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rasekhi</surname><given-names>Hamid</given-names></name><address><email>Rasekhi.h@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Karandish</surname><given-names>Majid</given-names></name><address><email>mkarandish@yahoo.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jalali</surname><given-names>Mohammad-Taha</given-names></name><address><email>jalali-mt@ajums.ac.ir</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Mohammadshahi</surname><given-names>Majid</given-names></name><address><email>Shahi334@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zarei</surname><given-names>Mehdi</given-names></name><address><email>Zarei@scu.ac.ir</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Saki</surname><given-names>Azadeh</given-names></name><address><email>Azadehsaki@yahoo.com</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Shahbazian</surname><given-names>Hajieh</given-names></name><address><email>Hjb_shahbazian@yahoo.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><aff id="Aff1"><label/>Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran </aff><aff id="Aff2"><label/>Hyperlipidemia Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran </aff><aff id="Aff3"><label/>Department of Food Hygiene, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran </aff><aff id="Aff4"><label/>Department of Biostatistics and Epidemiology, School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran </aff><aff id="Aff5"><label/>Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>14</volume><issue>1</issue><elocation-id>1</elocation-id><history><date date-type="received"><day>6</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Rasekhi et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Vitamin K, as a cofactor in the gamma carboxylation of certain glutamic acid (Gla) residues, has been related to glucose metabolism and insulin sensitivity. Osteocalcin, also known as bone &#x003b3;-carboxyglutamic acid, increases &#x003b2;-cell proliferation as well as insulin and adiponectin secretion, which improve glucose tolerance and insulin sensitivity. Thus, the purpose of the present study was to examine the possible role of adiponectin as a mediator of glucose homeostasis following phylloquinone supplementation in premonopause women with prediabetes.</p></sec><sec><title>Methods</title><p>Eighty two women were randomized to consume vitamin k1 supplement (n&#x02009;=&#x02009;39) or placebo (n&#x02009;=&#x02009;43) for four weeks. Participants in vitamin K1 treatment group received one pearl softgel capsule containing 1000 micrograms phylloquinone while the placebo group received one placebo capsules daily for four weeks. The Blood samples were collected at baseline and after a four-week intervention to quantify osteocalcin, adiponectin, leptin and relevant variables.</p></sec><sec><title>Results</title><p>Phylloquinone supplementation significantly increased serum adiponectin concentration (1.24&#x02009;&#x000b1;&#x02009;1.90 compared with &#x02212;0.27&#x02009;&#x000b1;&#x02009;1.08&#x000a0;&#x003bc;g/ml), and did not alter total osteocalcin (0.50&#x02009;&#x000b1;&#x02009;4.11 compared with 0.13&#x02009;&#x000b1;&#x02009;1.85&#x000a0;ng/ml) and leptin (&#x02212;0.29&#x02009;&#x000b1;&#x02009;8.23 compared with &#x02212;1.15&#x02009;&#x000b1;&#x02009;5.25&#x000a0;ng/ml) compared with placebo. Adjustments for total osteocalcin and adiponectin using analysis of covariance (ANCOVA) did not affect the association of glycemic status with related variables.</p></sec><sec><title>Conclusions</title><p>In conclusion our study demonstrated that phylloquinone supplementation improved glycemic status in premonopausal prediabetic women independent of adiponectin.</p></sec><sec><title>Trial registration</title><p>This trial was registered in Iranian Registry of Clinical Trials with ID number of <ext-link ext-link-type="uri" xlink:href="http://www.irct.ir/">IRCT2013120915724N1</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Phylloquinone</kwd><kwd>Vitamin K1</kwd><kwd>Osteocalcin</kwd><kwd>Adiponectin</kwd><kwd>Prediabetes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Vitamin K is a fat-soluble vitamin that functions as a cofactor in the gamma carboxylation of certain glutamic acid (Gla) residues of vitamin K dependent proteins such as osteocalcin [<xref ref-type="bibr" rid="CR1">1</xref>]. Studies in animal models showed osteocalcin (OC), an extracellular matrix component secreted by osteoblast in the bone, to be the mediator of energy metabolism in bone, pancreas and adipose tissue. In addition, OC in its undercarboxylated form (ucOC) also enhanced insulin sensitivity by up-regulating adiponectin expression in adipose tissues [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>]. Also, Circulating undercarboxylated osteocalcin is an index of the vitamin K status decreases in response to vitamin K supplementation [<xref ref-type="bibr" rid="CR4">4</xref>]. Several epidemiological studies have examined the association of vitamin K intake and glycemic status and insulin homeostasis. Higher intake of vitamin k also vitamin k supplementation has been associated to reduction in insulin resistance and improved glycemic status [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR10">10</xref>]. These findings are in contrast to some other studies which, based on animal models, anticipate reduction in ucOC levels by increasing vitamin k intake and hence results in adverse effects on glycemic status. Therefore, it is likely that vitamin K exerts its influence on glycemic status through other mechanisms.Therefore, in this study the effect of vitamin K supplementation on osteocalcin and adiponectin and consequently their impact on glucose and insulin homeostasis was investigated.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Subjects</title><p>A randomized, double-blinded, placebo controlled clinical trial was designed conducted over a total period of four weeks. This clinical trial was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences. Written informed consent was obtained from all study participants. Premenopausal women with diagnosed prediabetes with ages 22 to 45&#x000a0;years and body mass index (BMI) of 18.5 to 30&#x000a0;kg/m2 were eligible for the study. Subjects were recruited based on the results of a standard 75-g Oral Glucose Tolerance Test (OGTT) at screening (blood drawn in the 0 and 120&#x000a0;min), according to the American Diabetes Association criteria [<xref ref-type="bibr" rid="CR11">11</xref>]: Predibetes (PDM) was diagnosed according to the criteria established by the American Diabetes Association, i.e., impaired fasting glucose (IFG) (100&#x02009;&#x0003c;&#x02009;fasting plasma glucose (FPG)&#x02009;&#x0003c;&#x02009;126) or impaired Glucose test (IGT) (140&#x02009;&#x0003c;&#x02009;glucose120 min &#x0003c;200).</p><p>A total of 82 prediabetes women met the inclusion criteria. None of the subjects suffered rheumatic, thyroid, parathyroid, kidney, or liver disease, pregnancy, lactation, menopause and drugs known to influence glucose, vitamin k and bone metabolism like insulin and glucose, lipid-lowering drugs, warfarin, corticosteroids, vitamin and mineral supplements within six months. Overall, 82 women were randomized to consume vitamin k1supplement (n&#x02009;=&#x02009;39) or placebo (n&#x02009;=&#x02009;43) for four weeks. Participants in vitamin K1 treatment group received one pearl softgel capsule containing 1000 micrograms phylloquinone (DSM Nutritional Products, Inc, Switzerland) while the placebo group received one placebo capsules (Barij Essence Co. Iran) daily for four weeks. Placebo capsules were similar in color, shape, size appearance, and packaging and were indistinguishable for participants and investigators. The participants were asked to maintain their habitual food consumption, body weight and physical activity pattern throughout the study and not to consume any supplements other than the one provided to them by the investigator. Dietary intake was assessed using a three-day food record consisting of three non-consecutive days, including two week days and one weekend day. The dietary records were based on estimated values in household measurements. To obtain nutrient intakes of participants on the basis of these 3-d food diaries, we used Nutritionist IV software (First Databank) modified for Iranian foods. The short form of IPAQ consists of seven questions assessing the frequency and duration of participation in vigorous, moderate and walking activity and the time spent sitting during the last week was used to determine physical activity levels [<xref ref-type="bibr" rid="CR12">12</xref>]. The Persian translation of this questionnaire has previously been validated [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec4"><title>Assessment of variables</title><p>Body mass index and body fat were measured before and after the intervention. Body weight was measured to the nearest 0.1&#x000a0;kg after overnight fasting, without shoes and wearing minimal clothing, by the use of a digital scale (Seca). Height was measured to the nearest 0.1&#x000a0;cm by using a non-stretched tape measure (Seca). BMI was calculated as weight in kilograms divided by height in meters squared (kg/m<sup>2</sup><italic>)</italic>. The body fat was measured by OMRON BF 306 (Dalian, China) body fat monitor using bioelectric impedance. The Blood samples (10&#x000a0;ml) were collected at baseline and after a four-week intervention. After an overnight fast, 75&#x000a0;g OGTT was given to each subject between 8&#x000a0;a.m. and 10&#x000a0;a.m. Plasma glucose was determined at times 0 and 120&#x000a0;min after OGTT on the same day. Then the remaining separated serum stored at &#x02212;70 C before analysis in the laboratory of Ahvaz Jundishapur University of Medical Sciences. Serum carboxylated and undercarboxylated osteocalcin (cOC and ucOC) were measured blood serum using Takara Bio Inc., EIA kits (MK118 and MK111, respectively, Bio Inc., Japan,). Total OC (tOC) was estimated as the sum of cOC and ucOC [<xref ref-type="bibr" rid="CR14">14</xref>]. Adiponectin and leptin were quantitatively determined using a commercially available enzyme immunoassay (EIA) kit from Boster (china). Serum insulin (INS) was assayed by using an ELISA kit (Q-1-DIAPLUS, USA); Fasting blood glucose (FBG) and 2-h post-OGTT glucose were measured by auto-analyser (Hitachi, USA); hemoglobin A1C (HbA1c) was measured with HLC-723G8 (Tosoh Co., Tokyo, Japan) by high performance liquid chromatography (HPLC). Insulin resistance was calculated with HOMA-IR, which was defined as: HOMA-IR&#x02009;=&#x02009;[FPS (mg/DL)*fasting insulin (FINS (&#x003bc;U/ml)]/405. Basal insulin secretion which was calculated by using the following formula HOMA-%B:360*FINS(&#x003bc;U/ml)/(FPG-63) [<xref ref-type="bibr" rid="CR15">15</xref>]. Quantitative insulin sensitivity check index (QUICKI) were calculated on the basis of suggested formulas: 1/[log (Insulin &#x003bc;U/ml)&#x02009;+&#x02009;log (Glucose mg/DL)] [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec5"><title>Statistical analyses</title><p>Data are expressed as means&#x02009;&#x000b1;&#x02009;SDs. The normality of data distribution was assessed by using the Kolmogorov-Smirnov goodness-of-fit test. Two-factor repeated-measures analysis of variance (ANOVA) was used to test time*group interactions, with time and treatment as factors. In case of a significant time*group interaction, a between-group comparison of changes at 4&#x000a0;weeks was done by Independent-samples Student&#x02019;s t test analysis. When the time effect was significant, the within-group comparison of values was performed by the paired-samples t test. Differences in proportions were evaluated by using a chi-square test. ANCOVA was performed to examine the association between supplementation group and measure of insulin sensitivity and glucose. All statistical analyses were done by using the Statistical Package for Social Sciences (SPSS version 16; SPSS Inc, Chicago, IL). The P&#x02009;&#x0003c;&#x02009;0.05 was considered significant.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results and discussion</title><sec id="Sec7"><title>Results</title><p>The means and standard deviations for age, weight, and BMI were 40.17&#x02009;&#x000b1;&#x02009;4.9&#x000a0;years, 71&#x02009;&#x000b1;&#x02009;6.5&#x000a0;kg, and 28.08&#x02009;&#x000b1;&#x02009;1.65&#x02009;<italic>kg</italic>/<italic>m</italic><sup><italic>2</italic></sup>, respectively. Most of the women were overweight and BMI distribution was not significantly different between two groups. According to the IPAQ questionnaire, the both groups had the same low level of physical activity. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows the baseline and end-of-trial characteristics of the participants. Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows their dietary intakes of relevant nutrients. No significant difference existed between phylloquinone and placebo groups. Baseline values of total osteocalcin, adiponectin, leptin, FBS, 2-h post-OGTT glucose, fasting and 2-h post-OGTT insulin have been shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The time effects were statistically significant on adiponectin, FBS, 2-h post-OGTT glucose and 2-h post-OGTT insulin. Also the time*group interaction effects on adiponectin and 2-h post-OGTT glucose were significant (all P, 0.001). Intake of phylloquinone supplement led to significant decrease in 2&#x000a0;h post-OGTT glucose (&#x02212;10.87&#x02009;&#x000b1;&#x02009;27.41 compared with 1.20&#x02009;&#x000b1;&#x02009;18.63&#x000a0;mg/dl), 2&#x000a0;h post-OGTT insulin level (&#x02212;17.46&#x02009;&#x000b1;&#x02009;44.97 compared with 5.88&#x02009;&#x000b1;&#x02009;23.65 &#x003bc;IU/ml) and a significant increase in serum adiponectin concentration (1.24&#x02009;&#x000b1;&#x02009;1.90 compared with &#x02212;0.27&#x02009;&#x000b1;&#x02009;1.08&#x000a0;&#x003bc;g/ml) compared with placebo. We did not find any significant effect of phylloquinone supplementation on total osteocalcin, leptin and related glycemic and insulin variables. To evaluate the effect of each of the total osteocalcin and adiponectin on the changes of glucose and insulin levels between groups, we adjusted them for tOC and adiponectin (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>General characteristics of premenopausal women with PDM who received either vitamin K1 supplements or placebo</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Placebo group (n&#x02009;=&#x02009;43)</bold>
</th><th>
<bold>Phylloquinone group (n&#x02009;=&#x02009;39)</bold>
</th><th>
<bold>P value</bold>
</th></tr></thead><tbody><tr valign="top"><td>Age (y)</td><td>40.09&#x02009;&#x000b1;&#x02009;4.65</td><td>40.25&#x02009;&#x000b1;&#x02009;5.32</td><td>0.88*</td></tr><tr valign="top"><td>Weight (kg) at study baseline</td><td>71.09&#x02009;&#x000b1;&#x02009;6.59</td><td>71.21&#x02009;&#x000b1;&#x02009;6.47</td><td>0.93*</td></tr><tr valign="top"><td>Weight (kg) at end of trial</td><td>71&#x02009;&#x000b1;&#x02009;6.76</td><td>70.72&#x02009;&#x000b1;&#x02009;6.39</td><td>0.84*</td></tr><tr valign="top"><td>BMI (18.5-24.9&#x000a0;kg/m<sup>2</sup>) at study baseline</td><td>1(2.3%)</td><td>3(7.7%)</td><td>0.342**</td></tr><tr valign="top"><td>BMI (18.5-24.9&#x000a0;kg/m<sup>2</sup>) at the end of trial</td><td>2(4.7%)</td><td>5(12.8%)</td><td>0.249**</td></tr><tr valign="top"><td>BMI (25&#x02013;29.9&#x000a0;kg/m<sup>2</sup>) ) at study baseline</td><td>42(97.7%)</td><td>36(92.3%)</td><td>0.342**</td></tr><tr valign="top"><td>BMI (25&#x02013;29.9&#x000a0;kg/m<sup>2</sup>) at the end of trial</td><td>41(95.3%)</td><td>34(87.2%)</td><td>0.249**</td></tr><tr valign="top"><td>FM (%) at study baseline</td><td>38.55&#x02009;&#x000b1;&#x02009;3.99</td><td>38.77&#x02009;&#x000b1;&#x02009;3.86</td><td>0.79*</td></tr><tr valign="top"><td>FM (%) at end of trial</td><td>38.57&#x02009;&#x000b1;&#x02009;4.10</td><td>38.46&#x02009;&#x000b1;&#x02009;4.05</td><td>0.90*</td></tr><tr valign="top"><td>HbA<sub>1</sub>C (%) at study baseline</td><td>5.91&#x02009;&#x000b1;&#x02009;0.49</td><td>5.81&#x02009;&#x000b1;&#x02009;0.64</td><td>0.42*</td></tr></tbody></table><table-wrap-foot><p>All values are means&#x02009;&#x000b1;&#x02009;SDs.</p><p>*Obtained from independent-samples t test.</p><p>**Obtained from chi-square test.</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Dietary intakes of prediabetic women who received either vitamin K1 supplements or placebo throughout the study</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Placebo group (n&#x02009;=&#x02009;43)</bold>
</th><th>
<bold>Vitamin K1 group (n&#x02009;=&#x02009;39)</bold>
</th><th>
<bold>P value</bold>
<sup><bold>1</bold></sup>
</th></tr></thead><tbody><tr valign="top"><td>Energy (kcal/d)</td><td>1769&#x02009;&#x000b1;&#x02009;275</td><td>1819&#x02009;&#x000b1;&#x02009;272</td><td>0.42</td></tr><tr valign="top"><td>Carbohydrate (g/d)</td><td>243.12&#x02009;&#x000b1;&#x02009;37.76</td><td>249.60&#x02009;&#x000b1;&#x02009;39.20</td><td>0.44</td></tr><tr valign="top"><td>Protein (g/d)</td><td>75.04&#x02009;&#x000b1;&#x02009;12.75</td><td>77.56&#x02009;&#x000b1;&#x02009;11.60</td><td>0.35</td></tr><tr valign="top"><td>Fat (g/d)</td><td>64.90&#x02009;&#x000b1;&#x02009;10.05</td><td>66.32&#x02009;&#x000b1;&#x02009;10.34</td><td>0.52</td></tr><tr valign="top"><td>Vitamin k (&#x003bc;g/d)</td><td>57.16&#x02009;&#x000b1;&#x02009;19.03</td><td>62.69&#x02009;&#x000b1;&#x02009;15.45</td><td>0.15</td></tr><tr valign="top"><td>Vitamin D (mg/d)</td><td>3.7&#x02009;&#x000b1;&#x02009;1.6</td><td>4.06&#x02009;&#x000b1;&#x02009;1.67</td><td>0.32</td></tr><tr valign="top"><td>Calcium (mg/d)</td><td>719.38&#x02009;&#x000b1;&#x02009;261</td><td>677.0&#x02009;&#x000b1;&#x02009;237.97</td><td>0.44</td></tr></tbody></table><table-wrap-foot><p>All values are means&#x02009;&#x000b1;&#x02009;SDs.</p><p>
<sup>1</sup>Obtained from independent-samples t test.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Metabolic variables, biomarkers of insulin resistance and comparison of changes within and between placebo and phylloquinone groups</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="3">
<bold>Placebo group (n&#x02009;=&#x02009;43)</bold>
</th><th colspan="3">
<bold>Phylloquinone group (n&#x02009;=&#x02009;39)</bold>
</th><th/></tr><tr valign="top"><th/><th>
<bold>Week0</bold>
</th><th>
<bold>Week4</bold>
</th><th>
<bold>Change</bold>
</th><th>
<bold>Week0</bold>
</th><th>
<bold>Week4</bold>
</th><th>
<bold>Change</bold>
</th><th>
<bold>P value</bold>
<sup><bold>1</bold></sup>
</th></tr></thead><tbody><tr valign="top"><td>Total Osteocalcin (ng/ml)</td><td>11.95&#x02009;&#x000b1;&#x02009;5.76</td><td>12.08&#x02009;&#x000b1;&#x02009;5.65</td><td>0.13&#x02009;&#x000b1;&#x02009;1.85</td><td>14.50&#x02009;&#x000b1;&#x02009;5.81</td><td>15.01&#x02009;&#x000b1;&#x02009;6.51</td><td>0.50&#x02009;&#x000b1;&#x02009;4.11</td><td>0.61</td></tr><tr valign="top"><td>leptin (ng/ml)</td><td>26.78&#x02009;&#x000b1;&#x02009;10.33</td><td>25.62&#x02009;&#x000b1;&#x02009;10.21</td><td>&#x02212;1.15&#x02009;&#x000b1;&#x02009;5.25</td><td>28.59&#x02009;&#x000b1;&#x02009;9.61</td><td>28.29&#x02009;&#x000b1;&#x02009;9.86</td><td>&#x02212;0.29&#x02009;&#x000b1;&#x02009;8.23</td><td>0.92</td></tr><tr valign="top"><td>Adiponectin (&#x003bc;g/ml)</td><td>8.81&#x02009;&#x000b1;&#x02009;1.54</td><td>8.54&#x02009;&#x000b1;&#x02009;1.87</td><td>&#x02212;0.27&#x02009;&#x000b1;&#x02009;1.08</td><td>9.19&#x02009;&#x000b1;&#x02009;1.80</td><td>10.44&#x02009;&#x000b1;&#x02009;1.20*</td><td>1.24&#x02009;&#x000b1;&#x02009;1.90</td><td>0.00</td></tr><tr valign="top"><td>FBS (mg/DL)</td><td>106.69&#x02009;&#x000b1;&#x02009;13.63</td><td>105.20&#x02009;&#x000b1;&#x02009;12.41</td><td>&#x02212;1.48&#x02009;&#x000b1;&#x02009;10.37</td><td>107.66&#x02009;&#x000b1;&#x02009;10.72</td><td>104&#x02009;&#x000b1;&#x02009;11.25*</td><td>&#x02212;3.12&#x02009;&#x000b1;&#x02009;9.22</td><td>0.45</td></tr><tr valign="top"><td>2-h-post-OGTT glucose (mg/DL)</td><td>155.27&#x02009;&#x000b1;&#x02009;15.97</td><td>156.48&#x02009;&#x000b1;&#x02009;26.44</td><td>1.20&#x02009;&#x000b1;&#x02009;18.63</td><td>143.84&#x02009;&#x000b1;&#x02009;35.30</td><td>132.97&#x02009;&#x000b1;&#x02009;27.37*</td><td>&#x02212;10.87&#x02009;&#x000b1;&#x02009;27.41</td><td>0.02</td></tr><tr valign="top"><td>FINS (&#x003bc;IU/ml)</td><td>23.83&#x02009;&#x000b1;&#x02009;12.08</td><td>23.80&#x02009;&#x000b1;&#x02009;8.28</td><td>&#x02212;0.02&#x02009;&#x000b1;&#x02009;8.92</td><td>20.74&#x02009;&#x000b1;&#x02009;9.90</td><td>20.56&#x02009;&#x000b1;&#x02009;8.04</td><td>&#x02212;0.18&#x02009;&#x000b1;&#x02009;5.92</td><td>0.92</td></tr><tr valign="top"><td>2-h-post-OGTT INS (&#x003bc;IU/ml)</td><td>106.55&#x02009;&#x000b1;&#x02009;46.96</td><td>112.43&#x02009;&#x000b1;&#x02009;53.19</td><td>5.88&#x02009;&#x000b1;&#x02009;23.65</td><td>97.80&#x02009;&#x000b1;&#x02009;54.50</td><td>80.34&#x02009;&#x000b1;&#x02009;42.24*</td><td>&#x02212;17.46&#x02009;&#x000b1;&#x02009;44.97</td><td>0.00</td></tr></tbody></table><table-wrap-foot><p>All values are means&#x02009;&#x000b1;&#x02009;SDs. *Different from week 0, P&#x02009;&#x0003c;&#x02009;0.05; OGTT, oral glucose tolerance test; INS, Insulin; FINS, Fasting insulin; FBS, Fasting blood sugar.</p><p>
<sup>1</sup>Obtained from independent-samples t test.</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Adjusted changes in metabolic variables in prediabetic women who received either vitamin K1 supplements or placebo</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Placebo group (n&#x02009;=&#x02009;43)</bold>
</th><th>
<bold>Vitamin K1 group (n&#x02009;=&#x02009;39)</bold>
</th><th>
<bold>P value</bold>
<sup><bold>1</bold></sup>
</th></tr></thead><tbody><tr valign="top"><td>FBS (mg/DL)</td><td/><td/><td/></tr><tr valign="top"><td>Model1</td><td>1.48&#x02009;&#x000b1;&#x02009;1.50</td><td>&#x02212;3.12&#x02009;&#x000b1;&#x02009;1.57</td><td>0.45</td></tr><tr valign="top"><td>Model2</td><td>&#x02212;1.46&#x02009;&#x000b1;&#x02009;1.51</td><td>&#x02212;3.13&#x02009;&#x000b1;&#x02009;1.58</td><td>0.45</td></tr><tr valign="top"><td>Model3</td><td>&#x02212;1.97&#x02009;&#x000b1;&#x02009;1.59</td><td>&#x02212;2.59&#x02009;&#x000b1;&#x02009;1.67</td><td>0.80</td></tr><tr valign="top"><td>2-h post-OGTT glucose (mg/DL)</td><td/><td/><td/></tr><tr valign="top"><td>Model1</td><td>1.20&#x02009;&#x000b1;&#x02009;3.54</td><td>&#x02212;10.87&#x02009;&#x000b1;&#x02009;3.71</td><td>0.02</td></tr><tr valign="top"><td>Model2</td><td>1.36&#x02009;&#x000b1;&#x02009;3.54</td><td>&#x02212;11.04&#x02009;&#x000b1;&#x02009;3.71</td><td>0.01</td></tr><tr valign="top"><td>Model3</td><td>2.48&#x02009;&#x000b1;&#x02009;3.74</td><td>&#x02212;12.28&#x02009;&#x000b1;&#x02009;3.95</td><td>0.01</td></tr><tr valign="top"><td>FINS (&#x003bc;IU/ml)</td><td/><td/><td/></tr><tr valign="top"><td>Model1</td><td>&#x02212;0.02&#x02009;&#x000b1;&#x02009;1.16</td><td>&#x02212;0.18&#x02009;&#x000b1;&#x02009;1.22</td><td>0.92</td></tr><tr valign="top"><td>Model2</td><td>0.003&#x02009;&#x000b1;&#x02009;1.17</td><td>&#x02212;0.21&#x02009;&#x000b1;&#x02009;1.23</td><td>0.89</td></tr><tr valign="top"><td>Model3</td><td>-.039&#x02009;&#x000b1;&#x02009;1.24</td><td>&#x02212;0.16&#x02009;&#x000b1;&#x02009;1.31</td><td>0.94</td></tr><tr valign="top"><td>2-h post-OGTT insulin (&#x003bc;IU/ml)</td><td/><td/><td/></tr><tr valign="top"><td>Model1</td><td>5.88&#x02009;&#x000b1;&#x02009;5.40</td><td>&#x02212;17.46&#x02009;&#x000b1;&#x02009;5.67</td><td>0.00</td></tr><tr valign="top"><td>Model2</td><td>5.69&#x02009;&#x000b1;&#x02009;5.41</td><td>&#x02212;17.25&#x02009;&#x000b1;&#x02009;5.60</td><td>0.00</td></tr><tr valign="top"><td>Model3</td><td>9.90&#x02009;&#x000b1;&#x02009;5.58</td><td>&#x02212;21.88&#x02009;&#x000b1;&#x02009;5.89</td><td>0.00</td></tr><tr valign="top"><td>HOMA-IR</td><td/><td/><td/></tr><tr valign="top"><td>Model1</td><td>&#x02212;0.05&#x02009;&#x000b1;&#x02009;0.32</td><td>&#x02212;0.22&#x02009;&#x000b1;&#x02009;.34</td><td>0.76</td></tr><tr valign="top"><td>Model2</td><td>-.05&#x02009;&#x000b1;&#x02009;0.32</td><td>&#x02212;0.22&#x02009;&#x000b1;&#x02009;0.34</td><td>0.71</td></tr><tr valign="top"><td>Model3</td><td>&#x02212;0.06&#x02009;&#x000b1;&#x02009;0.34</td><td>&#x02212;0.20&#x02009;&#x000b1;&#x02009;0.36</td><td>0.79</td></tr><tr valign="top"><td>HOMA-B</td><td/><td/><td/></tr><tr valign="top"><td>Model1</td><td>&#x02212;5.42&#x02009;&#x000b1;&#x02009;14.49</td><td>14.95&#x02009;&#x000b1;&#x02009;15.21</td><td>0.33</td></tr><tr valign="top"><td>Model2</td><td>4.84&#x02009;&#x000b1;&#x02009;14.50</td><td>14.31&#x02009;&#x000b1;&#x02009;15.23</td><td>0.36</td></tr><tr valign="top"><td>Model3</td><td>&#x02212;7.10&#x02009;&#x000b1;&#x02009;15.42</td><td>16.80&#x02009;&#x000b1;&#x02009;16.28</td><td>0.31</td></tr><tr valign="top"><td>QUICKI</td><td/><td/><td/></tr><tr valign="top"><td>Model1</td><td>&#x02212;0.004&#x02009;&#x000b1;&#x02009;0.002</td><td>&#x02212;0.001&#x02009;&#x000b1;&#x02009;0.002</td><td>0.43</td></tr><tr valign="top"><td>Model2</td><td>&#x02212;0.004&#x02009;&#x000b1;&#x02009;0.002</td><td>&#x02212;0.001&#x02009;&#x000b1;&#x02009;0.002</td><td>0.44</td></tr><tr valign="top"><td>Model3</td><td>&#x02212;0.004&#x02009;&#x000b1;&#x02009;0.002</td><td>&#x02212;0.00&#x02009;&#x000b1;&#x02009;0.003</td><td>0.33</td></tr></tbody></table><table-wrap-foot><p>All values are means&#x02009;&#x000b1;&#x02009;SEs. Model 1 show original raw data<bold>,</bold> Model 2 was adjusted for tOC; Model 3 was adjusted for adiponectin; tOC, Total osteocalcin; FBS, Fasting blood sugar; OGTT, Oral glucose tolerance test; FINS, Fasting insulin; HOMA-IR, Homeostasis model assessment insulin resistance index; HOMA-B, Homeostatic model assessment&#x02013;&#x003b2; cell function; QUICKI, Quantitative insulin sensitivity check index. <sup>1</sup>Obtained from ANCOVA.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Discussions</title><p>Several epidemiological studies have investigated the association between vitamin K intake and glycemic status. For instance, in a cross-sectional study of 2719 adults 26&#x02013;81 years of age, Yoshida et al. [<xref ref-type="bibr" rid="CR7">7</xref>] showed that higher intake of vitamin K was associated with better insulin sensitivity and lower post-challenge glucose levels. In addition, Beulens JW et al. [<xref ref-type="bibr" rid="CR5">5</xref>], found that higher intakes of vitamin K were associated with reduced risk of type 2 diabetes. In another study with similar results it was reported in a National Health and Nutrition Examination Survey (NHANES) 1999&#x02013;2004 that vitamin K intake in the highest, compared with the lowest, quintile was associated with lower prevalence of hyperglycemia as a component of metabolic syndrome [<xref ref-type="bibr" rid="CR6">6</xref>]. However, the exact mechanisms underlying the associations between vitamin k intakes, glycemic status and insulin homeostasis still remain unknown. One finding which could possibly help shed light on the mechanism has been reported by Lee et al. [<xref ref-type="bibr" rid="CR3">3</xref>]. They demonstrated that osteocalcin, a vitamin-K-dependent protein in bone, is involved in glucose metabolism by increasing insulin secretion and cell proliferation in pancreatic &#x003b2;-cells and by upregulating the expression of the adiponectin gene in adipocytes, thus improving insulin sensitivity. This study was devised as a first study of its kind, to explore the impacts of the carboxylation of Osteocalcin by vitamin K and the mediation effects of adiponectin in prediabetic, premonopause women. In this study, it was observed that phylloquinone supplementation for four weeks significantly increased serum adiponectin, decreased 2-h post-OGTT glucose and did not change the other related variables compared with placebo. In contrast, Knapen MH [<xref ref-type="bibr" rid="CR17">17</xref>] found that Supplementation with vitamin K did not affect circulating adiponectin concentrations. Choi et al. [<xref ref-type="bibr" rid="CR18">18</xref>] also reported that no significant alterations were seen in fasting plasma glucose and adiponectin concentrations in serum with 4&#x000a0;weeks Vitamin K2 Supplementation in healthy young male subjects. Cross sectional studies have also pointed to the relationships between these variables. Kanazawa et al. [<xref ref-type="bibr" rid="CR19">19</xref>] found that that ucOC/OC ratio positively correlated with serum adiponectin level in men. Reinehr T [<xref ref-type="bibr" rid="CR20">20</xref>] studied obese children and found no significant relationship between adiponectin and osteocalcin. Meanwhile, another study failed to show such an association between adiponectin and osteocalcin [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>In the current study, analysis of covariance was performed to determine the role of either osteocalcin or adiponectin in glucose and insulin homeostasis. It was observed that adjustments for total steocalcin and adiponectin did not alter the associations of the related variables to glycemic status. Along the same lines, Shea et al. [<xref ref-type="bibr" rid="CR22">22</xref>] reported that the strength of the association between total osteocalcin and carboxylated osteocalcin with HOMA-IR was somewhat attenuated after adiponectin was accounted for; therefore, they concluded that the association between total osteocalcin and carboxylated osteocalcin with HOMA-IR may depend partially on adiponectin. Chen X et al. [<xref ref-type="bibr" rid="CR23">23</xref>] reported that the negative association between HOMA-IR and tOC remained significant after being controlled for adiponectin. In Hwang YC et al. study [<xref ref-type="bibr" rid="CR24">24</xref>] on adult subjects, it was reported that although the circulating osteocalcin level was associated with improved glucose tolerance and insulin secretion, this was independent of the plasma adiponectin level.</p><p>Although these studies and their contradictory results have considered the relationships between adiponectin and osteocalcin, it seems vitamin K probably influence Glycemic status through other mechanisms.</p></sec></sec><sec id="Sec9" sec-type="conclusion"><title>Conclusions</title><p>Finally although this study could not provide the underlying mechanism we speculate that vitamin K1 supplementation could modulate glycemic status by mechanism other total osteocalcin and adiponectin in premonopausal prediabetes women. In conclusion our study demonstrated that phylloquinone supplementation improved glycemic status in premenopausal prediabetic women independent of adiponectin.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>HR conceived the study, carried out the study, data analysis and drafted the manuscript. MK carried out the study, conceived the study, and drafted the manuscript. M-TJ carried out the study and helped data collection. MM participated in its design and helped ELISA. MZ carried out the ELISA. AS carried out data analysis and performed statistical analysis. HS carried out the study and helped data collection. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This paper is issued from the Ph.D thesis of Hamid Rasekhi, and the financial support was provided by Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences (Grant number NRC-9108). This trial was registered in Iranian Registry of Clinical Trials with ID number of IRCT2013120915724N1.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanahan</surname><given-names>CM</given-names></name><name><surname>Proudfoot</surname><given-names>D</given-names></name><name><surname>Farzaneh-Far</surname><given-names>A</given-names></name><name><surname>Weissberg</surname><given-names>PL</given-names></name></person-group><article-title>The role of Gla proteins in vascular calcification</article-title><source>Critical reviews in eukaryotic gene expression</source><year>1998</year><volume>8</volume><issue>3&#x02013;4</issue><fpage>357</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1615/CritRevEukarGeneExpr.v8.i3-4.60</pub-id><pub-id pub-id-type="pmid">9807700</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferron</surname><given-names>M</given-names></name><name><surname>Hinoi</surname><given-names>E</given-names></name><name><surname>Karsenty</surname><given-names>G</given-names></name><name><surname>Ducy</surname><given-names>P</given-names></name></person-group><article-title>Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><issue>13</issue><fpage>5266</fpage><lpage>5270</lpage><pub-id pub-id-type="doi">10.1073/pnas.0711119105</pub-id><pub-id pub-id-type="pmid">18362359</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>NK</given-names></name><name><surname>Sowa</surname><given-names>H</given-names></name><name><surname>Hinoi</surname><given-names>E</given-names></name><name><surname>Ferron</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>JD</given-names></name><name><surname>Confavreux</surname><given-names>C</given-names></name><name><surname>Dacquin</surname><given-names>R</given-names></name><name><surname>Mee</surname><given-names>PJ</given-names></name><name><surname>McKee</surname><given-names>MD</given-names></name><name><surname>Jung</surname><given-names>DY</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Mauvais-Jarvis</surname><given-names>F</given-names></name><name><surname>Ducy</surname><given-names>P</given-names></name><name><surname>Karsenty</surname><given-names>G</given-names></name></person-group><article-title>Endocrine regulation of energy metabolism by the skeleton</article-title><source>Cell</source><year>2007</year><volume>130</volume><issue>3</issue><fpage>456</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.05.047</pub-id><pub-id pub-id-type="pmid">17693256</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>SL</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><name><surname>O&#x02019;Brien-Morse</surname><given-names>M</given-names></name><name><surname>McKeown</surname><given-names>NM</given-names></name><name><surname>Wood</surname><given-names>RJ</given-names></name><name><surname>Saltzman</surname><given-names>E</given-names></name><name><surname>Gundberg</surname><given-names>CM</given-names></name></person-group><article-title>Effects of a hydrogenated form of vitamin K on bone formation and resorption</article-title><source>Am J Clin Nutr</source><year>2001</year><volume>74</volume><issue>6</issue><fpage>783</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">11722960</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beulens</surname><given-names>JW</given-names></name><name><surname>van der A</surname><given-names>D</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Sluijs</surname><given-names>I</given-names></name><name><surname>Spijkerman</surname><given-names>AM</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name></person-group><article-title>Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>8</issue><fpage>1699</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.2337/dc09-2302</pub-id><pub-id pub-id-type="pmid">20424220</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Jackson</surname><given-names>RT</given-names></name></person-group><article-title>Dietary phylloquinone intakes and metabolic syndrome in US young adults</article-title><source>J Am Coll Nutr</source><year>2009</year><volume>28</volume><issue>4</issue><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1080/07315724.2009.10718099</pub-id><pub-id pub-id-type="pmid">20368375</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Booth</surname><given-names>SL</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Saltzman</surname><given-names>E</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name></person-group><article-title>Phylloquinone intake, insulin sensitivity, and glycemic status in men and women</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>88</volume><issue>1</issue><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">18614743</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Saltzman</surname><given-names>E</given-names></name><name><surname>Shea</surname><given-names>MK</given-names></name><name><surname>Gundberg</surname><given-names>C</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name><name><surname>Dallal</surname><given-names>G</given-names></name><name><surname>Booth</surname><given-names>SL</given-names></name></person-group><article-title>Effect of vitamin K supplementation on insulin resistance in older men and women</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><issue>11</issue><fpage>2092</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.2337/dc08-1204</pub-id><pub-id pub-id-type="pmid">18697901</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibarrola-Jurado</surname><given-names>N</given-names></name><name><surname>Salas-Salvado</surname><given-names>J</given-names></name><name><surname>Martinez-Gonzalez</surname><given-names>MA</given-names></name><name><surname>Bullo</surname><given-names>M</given-names></name></person-group><article-title>Dietary phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease</article-title><source>Am J Clin Nutr</source><year>2012</year><volume>96</volume><issue>5</issue><fpage>1113</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.3945/ajcn.111.033498</pub-id><pub-id pub-id-type="pmid">23034962</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juanola-Falgarona</surname><given-names>M</given-names></name><name><surname>Salas-Salvado</surname><given-names>J</given-names></name><name><surname>Estruch</surname><given-names>R</given-names></name><name><surname>Portillo</surname><given-names>MP</given-names></name><name><surname>Casas</surname><given-names>R</given-names></name><name><surname>Miranda</surname><given-names>J</given-names></name><name><surname>Martinez-Gonzalez</surname><given-names>MA</given-names></name><name><surname>Bullo</surname><given-names>M</given-names></name></person-group><article-title>Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk</article-title><source>Cardiovascular diabetology.</source><year>2013</year><volume>12</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-7</pub-id><pub-id pub-id-type="pmid">23298335</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetic Associations</collab></person-group><article-title>Diagnosis and classification of diabetes mellitus</article-title><source>Diab Care</source><year>2011</year><volume>34</volume><issue>Suppl 1</issue><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.2337/dc11-S062</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">International Physical Activity Questionnaire. IPAQ Research Committee Guidelines for the Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)-Short and Long Forms. 2005. <ext-link ext-link-type="uri" xlink:href="http://www.ipaq.ki.se/scoring.pdf">www.ipaq.ki.se/scoring.pdf</ext-link>. Accessed 10 Jun 2014</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghaddam</surname><given-names>MHBAF</given-names></name><name><surname>Jafarabadi</surname><given-names>MA</given-names></name><name><surname>Allahverdipour</surname><given-names>H</given-names></name><name><surname>Nikookheslat</surname><given-names>SD</given-names></name><name><surname>Safarpour</surname><given-names>S</given-names></name></person-group><article-title>The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability</article-title><source>World Applied Sciences Journal</source><year>2012</year><volume>18</volume><issue>8</issue><fpage>1073</fpage><lpage>1080</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>HS</given-names></name><name><surname>Hwang</surname><given-names>IC</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>KK</given-names></name></person-group><article-title>Relationships between serum osteocalcin, leptin and the effect of weight loss by pharmacological treatment in healthy, nonsmoking Korean obese adults</article-title><source>Clin Chim Acta.</source><year>2013</year><volume>418</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2012.11.029</pub-id><pub-id pub-id-type="pmid">23247052</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><issue>7</issue><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id><pub-id pub-id-type="pmid">3899825</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>MH</given-names></name><name><surname>Singh</surname><given-names>BM</given-names></name><name><surname>Wise</surname><given-names>PH</given-names></name><name><surname>Carter</surname><given-names>G</given-names></name><name><surname>Alaghband-Zadeh</surname><given-names>J</given-names></name></person-group><article-title>A simple measure of insulin resistance</article-title><source>Lancet</source><year>1995</year><volume>346</volume><issue>8967</issue><fpage>120</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)92143-5</pub-id><pub-id pub-id-type="pmid">7603193</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapen</surname><given-names>MH</given-names></name><name><surname>Schurgers</surname><given-names>LJ</given-names></name><name><surname>Shearer</surname><given-names>MJ</given-names></name><name><surname>Newman</surname><given-names>P</given-names></name><name><surname>Theuwissen</surname><given-names>E</given-names></name><name><surname>Vermeer</surname><given-names>C</given-names></name></person-group><article-title>Association of vitamin K status with adiponectin and body composition in healthy subjects: uncarboxylated osteocalcin is not associated with fat mass and body weight</article-title><source>Br J Nutr</source><year>2012</year><volume>108</volume><issue>6</issue><fpage>1017</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1017/S000711451100626X</pub-id><pub-id pub-id-type="pmid">22136751</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>An</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Jang</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Shin</surname><given-names>CS</given-names></name></person-group><article-title>Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><issue>9</issue><fpage>e147</fpage><pub-id pub-id-type="doi">10.2337/dc11-0551</pub-id><pub-id pub-id-type="pmid">21868771</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>I</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Yamauchi</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Kurioka</surname><given-names>S</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Sugimoto</surname><given-names>T</given-names></name></person-group><article-title>Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus</article-title><source>Osteoporos Int</source><year>2011</year><volume>22</volume><issue>1</issue><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1007/s00198-010-1184-7</pub-id><pub-id pub-id-type="pmid">20165834</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinehr</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>CL</given-names></name></person-group><article-title>A new link between skeleton, obesity and insulin resistance: relationships between osteocalcin, leptin and insulin resistance in obese children before and after weight loss</article-title><source>Int J Obes (Lond)</source><year>2010</year><volume>34</volume><issue>5</issue><fpage>852</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/ijo.2009.282</pub-id><pub-id pub-id-type="pmid">20065970</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abseyi</surname><given-names>N</given-names></name><name><surname>Siklar</surname><given-names>Z</given-names></name><name><surname>Berberoglu</surname><given-names>M</given-names></name><name><surname>Hacihamdioglu</surname><given-names>B</given-names></name><name><surname>Savas Erdeve</surname><given-names>S</given-names></name><name><surname>Ocal</surname><given-names>G</given-names></name></person-group><article-title>Relationships between osteocalcin, glucose metabolism, and adiponectin in obese children: Is there crosstalk between bone tissue and glucose metabolism?</article-title><source>Journal of clinical research in pediatric endocrinology</source><year>2012</year><volume>4</volume><issue>4</issue><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.4274/Jcrpe.831</pub-id><pub-id pub-id-type="pmid">23261860</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shea</surname><given-names>MK</given-names></name><name><surname>Gundberg</surname><given-names>CM</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Dallal</surname><given-names>GE</given-names></name><name><surname>Saltzman</surname><given-names>E</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><name><surname>Booth</surname><given-names>SL</given-names></name></person-group><article-title>Gamma-carboxylation of osteocalcin and insulin resistance in older men and women</article-title><source>Am J Clin Nutr</source><year>2009</year><volume>90</volume><issue>5</issue><fpage>1230</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2009.28151</pub-id><pub-id pub-id-type="pmid">19776145</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name></person-group><article-title>Osteocalcin is inversely associated with glucose levels in middle-aged Tibetan men with different degrees of glucose tolerance</article-title><source>Diabetes Metab Res Rev</source><year>2014</year><volume>30</volume><issue>6</issue><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1002/dmrr.2509</pub-id><pub-id pub-id-type="pmid">24339141</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>YC</given-names></name><name><surname>Jeong</surname><given-names>IK</given-names></name><name><surname>Ahn</surname><given-names>KJ</given-names></name><name><surname>Chung</surname><given-names>HY</given-names></name></person-group><article-title>Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level</article-title><source>Osteoporos Int</source><year>2012</year><volume>23</volume><issue>4</issue><fpage>1337</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1007/s00198-011-1679-x</pub-id><pub-id pub-id-type="pmid">21656264</pub-id></element-citation></ref></ref-list></back></article>